7/6/23, 12:56 PM Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm - UpToDate Official reprint from UpToDate www.uptodate.com 2023 UpToDate, Inc. and/or its affiliates. All Rights Reserved. Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm : Alejandro A Rabinstein, MD : Lawrence LK Leung, MD, Jos Biller, MD, FACP, FAAN, FAHA : Richard P Goddeau, Jr, DO, FAHA All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jun 2023. This topic last updated: Jul 20, 2022. INTRODUCTION Unruptured intracranial aneurysms are detected in up to 2 to 3 percent of older adults who undergo high-quality noninvasive intracranial arterial imaging (eg, magnetic resonance angiography, computed tomographic angiography). Subarachnoid hemorrhage from a ruptured intracranial aneurysm is associated with a short-term mortality of 40 percent, with one-half of survivors sustaining permanent neurologic injury. Thus, detection of an asymptomatic unruptured aneurysm creates a management dilemma in patients who have indications for antithrombotic therapy. (See "Unruptured intracranial aneurysms".) This topic review will discuss issues related to anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm. THEORETICAL EFFECTS OF ANTITHROMBOTIC MEDICATION USE Rates of rupture for previously detected unruptured aneurysms vary according to their size (ie, there is a greater risk of rupture in larger aneurysms), specific location (eg, higher rates of rupture with posterior circulation aneurysms) [1], as well as history of prior subarachnoid hemorrhage from a separate aneurysm [2]. This subject is reviewed in depth separately. (See "Unruptured intracranial aneurysms", section on 'Risk factors for aneurysm rupture'.) https://www.uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-an-unruptured-intracranial-aneurysm/print 1/9 7/6/23, 12:56 PM Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm - UpToDate It is not known whether antithrombotic therapies influence the rate of rupture of intracranial aneurysms. By reducing thrombus formation in the aneurysmal sac, it is possible that antithrombotic therapy could increase rates of aneurysm rupture. Antithrombotic and antiplatelet therapies also could exacerbate the severity of the hemorrhage in case of rupture, perhaps even converting intramural or minor subarachnoid hemorrhages into major, life- threatening bleeding. Conversely, aspirin could reduce the risk of rupture by inhibiting inflammatory mediators (such as matrix metalloproteinases and tumor necrosis factor-alpha) that might play a role in the evolution and eventual rupture of intracranial aneurysms [3,4]. Clinical data on these points are sparse, as summarized below. EFFECT OF ANTIPLATELET THERAPY Available clinical data are limited and conflicting regarding the influence of aspirin and other antiplatelet agents on rates of aneurysm rupture. Overall, chronic use of antiplatelets appears safe and might even be protective in patients with unruptured, asymptomatic intracranial aneurysms. In the Nurses' Health Study, a large prospective longitudinal cohort study, middle-aged females who used >15 aspirin per week had twice the rate of all-cause subarachnoid hemorrhage compared with nonusers [5]. The excess risk was particularly pronounced among older and hypertensive females and was not observed among those taking lower doses of aspirin. In this study, there were an unduly large number of subarachnoid hemorrhages relative to ischemic strokes and intraparenchymal hemorrhages, although the fraction of subarachnoid hemorrhages that were due to ruptured aneurysms was not reported. Despite multivariate statistical adjustments, imbalances in other vascular risk factors between aspirin users versus nonusers in observational trials leave etiologic associations unproven. In contrast, aspirin use at least three times weekly was associated with a lower risk of aneurysm rupture in a nested case-control study of the untreated cohort of patients in the International Study of Unruptured Intracranial Aneurysms (ISUIA; adjusted odds ratio [OR] 0.27, 95% CI 0.11-0.67) [3]. Aspirin also prevented intracranial aneurysm rupture in an experimental mouse model [6] and this effect is thought to be mediated by cyclooxygenase-2 inhibition [7]. A nationwide case-control study in Denmark found that recent initiation of aspirin, clopidogrel, or both was associated with increased risk of subarachnoid hemorrhage [8]. https://www.uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-an-unruptured-intracranial-aneurysm/print 2/9 7/6/23, 12:56 PM Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm - UpToDate However, this increased risk was restricted to the first three months after starting antiplatelet therapy and the assessment was based on relatively small numbers of patients. Risk of subarachnoid hemorrhage was not affected by longer-term use of antiplatelet agents. Meanwhile, a population-based Dutch case-control study found no association between use of antiplatelet agents and risk of subarachnoid hemorrhage [9]. Among patients with ischemic stroke, having an intracranial aneurysm did not result in excess risk of adverse outcomes related to antiplatelet therapy [10]. In a retrospective case series of 362 patients, no cases of subarachnoid hemorrhage occurred despite pretreatment with dual antiplatelet therapy for three months before stent-assisted coiling or flow diversion of unruptured (often large) intracranial aneurysm [11]. Regarding the severity of subarachnoid hemorrhage, data from clinical case series have shown no apparent increase in the initial severity of bleeding and no adverse effect on long-term outcome in patients presenting with aneurysmal subarachnoid hemorrhage who were taking aspirin prior to rupture [12-14]. In an analysis of the National Inpatient Sample including 11,549 patients with aneurysmal subarachnoid hemorrhage who were treated with surgical or endovascular aneurysm repair, aspirin use was not associated with in-hospital mortality but was associated with lower rates of cardiac complications and venous thromboembolic events. Furthermore, among patients treated with endovascular repair, the rate of poor outcomes was lower among aspirin users (32 versus 37 percent; OR 0.63, 95% CI 0.42-0.94) [15]. EFFECT OF ANTICOAGULATION No data supporting higher rupture rates following the use of anticoagulants are available from randomized clinical trials or large cohort studies. However, these studies do not convincingly exclude higher rates of aneurysmal subarachnoid hemorrhage in anticoagulated patients due to the infrequency of subarachnoid hemorrhage, which is typically combined with other causes of hemorrhagic strokes in reports of clinical trials. A population-based Dutch study noted an increased risk of subarachnoid hemorrhage in patients taking vitamin K antagonists on a case- crossover analysis (adjusted odds ratio [OR] 2.46, 95% CI 1.04-5.82), but the association was not significant on case-control and case-time-control analyses [9]. A Danish nationwide case-control study found an association between short-term (less than one month) of vitamin K antagonists and subarachnoid hemorrhage, but the association was not sustained with longer-term use of these drugs [8]. Among patients with ischemic stroke, presence of an intracranial aneurysm did not contribute to excess risk of adverse outcomes related to anticoagulation [10]. https://www.uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-an-unruptured-intracranial-aneurysm/print 3/9 7/6/23, 12:56 PM Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm - UpToDate Anticoagulation might worsen the clinical outcome of aneurysmal subarachnoid hemorrhage. Death or dependency following aneurysmal subarachnoid hemorrhage occurred in 93 percent (14 of 15) of anticoagulated patients versus 49 percent of those not receiving anticoagulants in one reported case series [16]. This was due to the worse clinical status at the time of admission of anticoagulated patients as a consequence of more severe initial bleeding. A study using a large registry of hospitalized patients in the United States (the National Inpatient Sample) found that anticoagulated patients had higher crude rates of in-hospital mortality (19 versus 13 percent) and poor outcome (54 versus 38 percent), but both of these findings were not significant on multivariable analysis [15]. EFFECT OF THROMBOLYSIS Limited data suggest that intravenous thrombolysis with recombinant tissue plasminogen activator (tPA) appears safe in patients with unruptured intracranial aneurysms who have an acute ischemic stroke [17,18]. This argues against an increased risk of rupture from the use of drugs that affect coagulation. MANAGEMENT American Heart Association guidelines [19,20] and major reviews [21] concerning management of unruptured intracranial aneurysms do not address the use of antiplatelet agents or anticoagulants. Given the available information as summarized above, it is not clear that antithrombotic therapies increase the risk of aneurysm rupture. However, the following observations have been made: Aspirin does not appear to be associated with worse clinical outcomes from aneurysmal subarachnoid hemorrhage, but the existing data are meager (see 'Effect of antiplatelet therapy' above). Consequently, at present, detection of an unruptured intracerebral aneurysm should not be regarded as a contraindication to antiplatelet therapy for patients who have a clear indication for such medication. Limited data suggest that anticoagulation with oral vitamin K inhibitors might worsen the severity of initial bleeding if rupture does occur (see 'Effect of anticoagulation' above). The potentially higher rates of death or disability observed after rupture of an intracranial aneurysm in patients taking anticoagulants should be considered in weighing the benefits versus risks of anticoagulation in patients known to harbor an unruptured intracranial aneurysm. https://www.uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-an-unruptured-intracranial-aneurysm/print 4/9 7/6/23, 12:56 PM Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm - UpToDate As an example, for an older adult patient with atrial fibrillation and prior stroke or transient ischemic attack who has a 10 mm unruptured aneurysm involving the anterior communicating artery, treatment with warfarin would be expected to produce an absolute reduction in the rate of stroke of approximately 6 percent per year (half of which are likely to be fatal or disabling) [22] but would augment the risk of fatal or disabling subarachnoid hemorrhage by approximately 0.25 percent per year [2,16]. In the absence of other risks, this analysis would lead one to favor anticoagulation in this particular patient. For those patients with larger aneurysms or those whose absolute benefits from anticoagulation are smaller, the estimated harm from anticoagulation may substantially mitigate its benefits. Thus, the decision must be individualized according to the best estimates of benefits versus risks. It is unclear how the need for chronic anticoagulation should influence the complex benefit/risk equation regarding repair of unruptured intracranial aneurysms [16,23,24]. Anticoagulation without aneurysm repair is reasonable for patients with a solid indication for anticoagulation who have aneurysms with a low estimated risk of rupture. For patients with aneurysms at higher risk of rupture, and those for whom the absolute benefits from anticoagulation are deemed smaller, the decision regarding the use of anticoagulation must be individualized according to the best estimates of benefits versus risks, accounting for patient values and preferences. Most experts do not consider a requirement for anticoagulation therapy to be an indication for aneurysm repair [25]. SOCIETY GUIDELINE LINKS Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Stroke in adults".) SUMMARY AND RECOMMENDATIONS Prevalence and complications of intracranial aneurysms Unruptured intracranial aneurysms are detected in 2 to 3 percent of older adults. Subarachnoid hemorrhage from a ruptured intracranial aneurysm is associated with high morbidity and mortality. (See "Unruptured intracranial aneurysms" and "Aneurysmal subarachnoid hemorrhage: Treatment and prognosis", section on 'Prognosis'.) Antiplatelet therapy Based upon limited evidence, daily use of regular doses of aspirin appears to be safe and there is preliminary evidence that it might even decrease the risk of https://www.uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-an-unruptured-intracranial-aneurysm/print 5/9 7/6/23, 12:56 PM Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm - UpToDate aneurysm rupture. The risks associated with other antiplatelet agents or with combination of antiplatelet agents are not known. (See 'Effect of antiplatelet therapy' above.) Anticoagulation Anticoagulation may exacerbate the degree of hemorrhage in case of rupture and may worsen the clinical outcome of aneurysmal subarachnoid hemorrhage. (See 'Effect of anticoagulation' above.) Individualized management Management of a patient with an unruptured intracranial aneurysm who requires treatment with an antiplatelet agent or anticoagulation for another indication requires careful evaluation of multiple factors. General principles Two general principles apply to these patients (see 'Management' above): Detection of an unruptured intracerebral aneurysm should not be regarded as a contraindication to antiplatelet therapy for patients who have a clear indication for such medication. Anticoagulation without treatment of the aneurysm is reasonable for patients with a solid indication for anticoagulation who have aneurysms with a low estimated risk of rupture. For patients with aneurysms at higher risk of rupture, and those for whom the absolute benefits from anticoagulation are deemed smaller, the decision regarding the use of anticoagulation must be individualized according to the best estimates of benefits versus risks, accounting for patient values and preferences. Assessment of individual risks Factors to be considered include the following (see 'Management' above): - - Risk of spontaneous rupture of the aneurysm (eg, size, location) Risk of thrombosis/stroke if antiplatelet/anticoagulant treatment is not given Risk of exacerbated bleeding from an aneurysmal rupture if anticoagulant treatment is given Use of UpToDate is subject to the Terms of Use. REFERENCES 1. Wermer MJ, van der Schaaf IC, Algra A, Rinkel GJ. Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics: an updated meta-analysis. Stroke 2007; 38:1404. https://www.uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-an-unruptured-intracranial-aneurysm/print 6/9 7/6/23, 12:56 PM Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm - UpToDate 2. Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362:103. 3. Hasan DM, Mahaney KB, Brown RD Jr, et al. Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke 2011; 42:3156. 4. Vergouwen MD, Rinkel GJ, Algra A, et al. Prospective Randomized Open-label Trial to evaluate risk faCTor management in patients with Unruptured intracranial aneurysms: Study protocol. Int J Stroke 2018; 13:992. 5. Iso H, Hennekens CH, Stampfer MJ, et al. Prospective study of aspirin use and risk of stroke in women. Stroke 1999; 30:1764. 6. Suzuki T, Kamio Y, Makino H, et al. Prevention Effect of Antiplatelets on Aneurysm Rupture in a Mouse Intracranial Aneurysm Model. Cerebrovasc Dis 2018; 45:180. 7. Starke RM, Chalouhi N, Ding D, Hasan DM. Potential role of aspirin in the prevention of aneurysmal subarachnoid hemorrhage. Cerebrovasc Dis 2015; 39:332. 8. Potteg rd A, Garc a Rodr guez LA, Poulsen FR, et al. Antithrombotic drugs and subarachnoid haemorrhage risk. A nationwide case-control study in Denmark. Thromb Haemost 2015; 114:1064. 9. Risselada R, Straatman H, van Kooten F, et al. Platelet aggregation inhibitors, vitamin K antagonists and risk of subarachnoid hemorrhage. J Thromb Haemost 2011; 9:517. 10. Shono Y, Sugimori H, Matsuo R, et al. Safety of antithrombotic therapy for patients with acute ischemic stroke harboring unruptured intracranial aneurysm. Int J Stroke 2018; 13:734. 11. Peret A, Mine B, Bonnet T, et al. Safety and efficacy of a pre-treatment antiplatelet regimen of unruptured intracranial aneurysms: a single-center experience. Neuroradiology 2020; 62:1029. 12. Juvela S. Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg 1995; 82:945. 13. Toussaint LG 3rd, Friedman JA, Wijdicks EF, et al. Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage. J Neurosurg 2004; 101:921. 14. Al-Mufti F, Ogulnick J, Feldstein E, et al. Impact of pre-ictal antiplatelet therapy use in aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 2021; 211:107022. 15. Dasenbrock HH, Yan SC, Gross BA, et al. The impact of aspirin and anticoagulant usage on outcomes after aneurysmal subarachnoid hemorrhage: a Nationwide Inpatient Sample analysis. J Neurosurg 2017; 126:537. https://www.uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-an-unruptured-intracranial-aneurysm/print 7/9 7/6/23, 12:56 PM Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm - UpToDate 16. Rinkel GJ, Prins NE, Algra A. Outcome of aneurysmal subarachnoid hemorrhage in patients on anticoagulant treatment. Stroke 1997; 28:6. 17. Edwards NJ, Kamel H, Josephson SA. The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature. Stroke 2012; 43:412. 18. Chiu WT, Hong CT, Chi NF, et al. The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm. PLoS One 2017; 12:e0180021. 19. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke 2012; 43:1711. 20. Thompson BG, Brown RD Jr, Amin-Hanjani S, et al. Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015; 46:2368. 21. Brown RD Jr, Broderick JP. Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screening. Lancet Neurol 2014; 13:393. 22. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857. 23. Wardlaw JM, White PM. The detection and management of unruptured intracranial aneurysms. Brain 2000; 123 ( Pt 2):205. 24. White PM, Wardlaw J. Unruptured intracranial aneurysms: prospective data have arrived. Lancet 2003; 362:90. 25. Etminan N, Beseoglu K, Barrow DL, et al. Multidisciplinary consensus on assessment of unruptured intracranial aneurysms: proposal of an international research group. Stroke 2014; 45:1523. Topic 1320 Version 15.0 Contributor Disclosures Alejandro A Rabinstein, MD Grant/Research/Clinical Trial Support: Chiesi [Small investigator-initiated project]. Consultant/Advisory Boards: AstraZeneca [Secondary stroke prevention]; Brainomix [AI for stroke diagnostics]; Novo Nordisk [Stroke risk]; Shionogi [Stroke neuroprotection]. Other Financial Interest: Boston Scientific [Adverse event adjudication committee member for stroke risk reduction device in patients with atrial fibrillation]. All of the relevant financial relationships listed have been mitigated. Lawrence LK Leung, MD No relevant financial relationship(s) with ineligible companies to disclose. Jos Biller, MD, FACP, FAAN, FAHA No relevant financial relationship(s) with ineligible companies to disclose. Richard P Goddeau, Jr, DO, FAHA No relevant financial relationship(s) with ineligible companies to disclose. https://www.uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-an-unruptured-intracranial-aneurysm/print 8/9 7/6/23, 12:56 PM Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm - UpToDate Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence. Conflict of interest policy https://www.uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-an-unruptured-intracranial-aneurysm/print 9/9